Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 11/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3036262 | 0.85 | GRIN1 (0.40) | CACNA1BPGRNR3C1NR3C2AR | |
| SCHEMBL3028107 | 0.84 | ITGB2 (0.42) | CACNA1BPGRNR3C1NR3C2AR | |
| SCHEMBL2786954 | 0.83 | PGR (0.38) | CACNA1BPGRNR3C1NR3C2AR | |
| SCHEMBL2804798 | 0.83 | CACNA1B (0.37) | CACNA1BPGRNR3C1NR3C2AR | |
| SCHEMBL3042679 | 0.82 | PIK3CA (0.36) | CACNA1BPGRNR3C1NR3C2AR | |
| SCHEMBL3033572 | 0.81 | GRIN1 (0.43) | CACNA1BPGRNR3C1NR3C2AR | |
| SCHEMBL3043842 | 0.80 | CACNA1B (0.37) | CACNA1BPGRNR3C1NR3C2AR | |
| SCHEMBL2806300 | 0.77 | ITGB2 (0.37) | CACNA1BPGRNR3C1NR3C2AR | |
| SCHEMBL8052840 | 0.76 | PGR (0.55) | CACNA1BPGRNR3C1NR3C2AR | |
| SCHEMBL3019210 | 0.76 | PGR (0.55) | CACNA1BPGRNR3C1NR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152568-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | AISA PHARMA, INC. | 2025-05-15 | — | — | US | claimed |
| EP-4475887-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | Aisa Pharma, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| WO-2024211216-A1 | CILNIDIPINE AND A P-GLYCOPROTEIN INHIBITOR FOR TREATING PAIN | AISA PHARMA, INC. (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2023150336-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | AISA PHARMA, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| EP-4683634-A1 | TREATMENT OF SCLERODERMA | Aisa Pharma, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4646205-A2 | COMBINATION THERAPIES FOR TREATMENT OF HEARING DISORDERS | Gateway Biotechnology, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250152568-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | AISA PHARMA, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-4523748-A2 | TREATMENT OF PAIN AND VASOCONSTRICTION | Aisa Pharma, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250017940-A1 | SELECTIVE PEPTIDOMIMETIC MODULATORS OF CAV2.2 (N-TYPE) VOLTAGE-GATED CALCIUM CHANNELS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4475887-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | Aisa Pharma, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240398771-A1 | TREATMENT OF SCLERODERMA AND RAYNAUD'S SYNDROME | AISA PHARMA, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4114466-B1 | TREATMENT OF PAIN AND VASOCONSTRICTION | AISA PHARMA INC (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4251164-A2 | TREATMENT OF RAYNAUD'S DISEASE | Aisa Pharma, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023150336-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | AISA PHARMA, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230115611-A1 | TREATMENT OF PAIN AND VASOCONSTRICTION | AISA PHARMA, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230073534-A1 | MODULATING TLR/NF-KB AND P53 SIGNALING PATHWAYS TO ENHANCE INTERSPECIES CHIMERISM BETWEEN EVOLUTIONARYILY DISTANT SPECIES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-03-09 | — | — | US | disclosed |
| EP-4114466-A1 | TREATMENT OF PAIN AND VASOCONSTRICTION | Aisa Pharma, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022115576-A9 | TREATMENT OF RAYNAUD'S DISEASE | AISA PHARMA, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022115576-A2 | TREATMENT OF RAYNAUD'S DISEASE | AISA PHARMA, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220168286-A1 | TREATMENT OF RAYNAUD'S DISEASE | AISA PHARMA, INC. | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017940-A1 | SELECTIVE PEPTIDOMIMETIC MODULATORS OF CAV2.2 (N-TYPE) VOLTAGE-GATED CALCIUM CHANNELS AND USES THEREOF | CACNA1B, CACNA1E, CACNA1D | CACNA1B 1/4885PGR 4085/4885NR3C1 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.